Allworth Financial LP Buys 1,720 Shares of Amgen Inc. (NASDAQ:AMGN)

Allworth Financial LP increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,755 shares of the medical research company's stock after acquiring an additional 1,720 shares during the quarter. Allworth Financial LP's holdings in Amgen were worth $11,451,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new position in shares of Amgen during the 4th quarter valued at about $26,000. First Pacific Financial lifted its stake in Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares during the last quarter. Ritter Daniher Financial Advisory LLC DE boosted its holdings in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares in the last quarter. Atala Financial Inc acquired a new position in Amgen in the fourth quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the fourth quarter valued at $36,000. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.76% of the stock is owned by company insiders.

Amgen Stock Down 1.7%

Shares of AMGN stock traded down $5.10 on Friday, hitting $295.27. The company's stock had a trading volume of 1,619,752 shares, compared to its average volume of 2,845,152. The stock has a market capitalization of $158.77 billion, a price-to-earnings ratio of 26.94, a P/E/G ratio of 2.72 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm's fifty day moving average price is $283.28 and its 200-day moving average price is $287.76. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.96 earnings per share. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AMGN shares. Morgan Stanley reiterated an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Piper Sandler reiterated an "overweight" rating and issued a $328.00 target price on shares of Amgen in a report on Friday, June 27th. William Blair reissued an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Mizuho upped their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $307.82.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.